Tackling myeloma bone disease: From pathophysiology to cutting-edge therapies

Area of Science:

• Hematology
• Oncology
• Bone Biology

Background:

• Multiple myeloma (MM) is characterized by significant bone involvement, leading to osteolytic lesions.
• This bone destruction results from an imbalance favoring excessive bone resorption over suppressed bone formation.
• The bone microenvironment, including myeloma cells, stromal cells, and immune cells, critically influences myeloma bone disease (MBD).

Purpose of the Study:

• To review recent findings on the pathogenesis of MM-associated bone disease.
• To discuss current and emerging therapeutic strategies targeting bone remodeling and myeloma progression.
• To highlight the complex interactions within the bone microenvironment in MBD.

Main Methods:

• Literature review of recent studies on multiple myeloma and bone disease.
• Analysis of molecular mechanisms driving osteolysis and impaired bone formation in MBD.
• Evaluation of therapeutic targets and novel treatment approaches.

Main Results:

• MM bone disease involves dysregulated osteoclast and osteoblast activity, with key pathways like RANK/RANKL and Wnt signaling implicated.
• Myeloma cell interactions with the bone marrow microenvironment are central to MBD pathogenesis.
• Emerging therapies, including molecularly targeted agents and microRNA-based approaches, show promise for managing MBD.

Conclusions:

• Understanding the intricate mechanisms of MBD is crucial for developing effective treatments.
• Therapeutic strategies must address both the underlying myeloma and the bone remodeling imbalance.
• Novel therapies offer potential for improved patient outcomes in MM with bone involvement.